Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Sep 24, 2020 (6 years ago)

Metformin Hydrochloride Tablets USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Presence of Foreign Tablets/Capsules: Metformin 1000mg with different imprint was found in bottles.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Metformin Hydrochloride Tablets USP, 1000 mg, 60-count bottles, Rx Only, Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045, Distributed by: Wal-Mart, Bentonville, AR 72716. NDC 68645-545-59

Affected NDC 68645-0545-59

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Recalling firm
Legacy Pharmaceutical Packaging LLC
NDC code
68645-545-59
Origin
MO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1626-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Legacy Pharmaceutical Packaging LLC

All 2020 recalls
Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)

Ongoing Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1263-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.

Terminated Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1075-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected

Ongoing Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-579-54 D-1050-2019